Can Genetic Clues Make Chemotherapy Safer for Children with Leukemia? A Systematic Review and Meta-Analysis of Toxicity Predictors and the Missing Evidence in BFM Protocols
Pediatric Hematology Oncology Journal · 2026-11 · 101191
DOI: 10.1016/j.phoj.2026.101191 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Pediatric Hematology Oncology Journal, 2026-11. Verfasst von Moses O. Alhassan und 2 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege, Kinderkrankenpflege
Abstract (Originalsprache)
: Background Germline variants have an effect in chemotherapy toxicity and outcomes in paediatric acute lymphoblastic leukaemia (ALL), although most data are non-Berlin-Frankfurt-Münster (BFM) .
Objective
To synthesise evidence in the 2020-25 timeframe on germline pharmacogenomic predictors of toxicity, treatment response, and clinical outcomes in paediatric ALL, specifically NUDT15 c.415C >T and in BFM-treated cohorts.
Methods
On 20 November 2025, PubMed/MEDLINE and Scopus were searched, with citation chasing being used to supplement the results. Articles that included children aged at the most 25 years old and had ALL but investigated germline variants that are associated with major chemotherapeutic agents were included. Records were screened and data extracted and risk of bias evaluated by 2 independent reviewers. More than 3 studies reported a pair of variant-outcomes which lead to the fixed-effect meta-analysis.
Results
Among 410 records that were screened, 87 studies were eligible to be qualitatively synthesized. There were 27 distinct studies that gave primary data on pharmacogenomics (n=4,847). T carriage of NUTD15 c.415C was significantly associated with severe (grade 34) myelosuppression induced by thiopurine (5 cohorts, n=554; pooled OR 9.25, 95% CI 5.60–15.29; I 2 =0%). Variants associated with methotrexate showed ancestry-specific effects and polygenic models had an AUC of 0.75-0.85 with composite toxicity. There were no pharmacogenomic research results found in BFM-treated cohorts even though 25 clinical trials reported the results in more than 15,000 BFM patients.
Conclusion
The strongest predictor of thiopurine toxicity in paediatric ALL is NUDT15 c. 415C. T. The lack of any germline pharmacogenomic data in BFM regimens is a critical translational gap. Future research that is enclosed in BFM procedures is highly anticipated.
Zitieren
APA
Alhassan, M. O., Dushimova, Z., & Milicevic, M. S. (2026). Can Genetic Clues Make Chemotherapy Safer for Children with Leukemia? A Systematic Review and Meta-Analysis of Toxicity Predictors and the Missing Evidence in BFM Protocols. Pediatric Hematology Oncology Journal, 101191. https://doi.org/10.1016/j.phoj.2026.101191
Vancouver
Alhassan MO, Dushimova Z, Milicevic MS. Can Genetic Clues Make Chemotherapy Safer for Children with Leukemia? A Systematic Review and Meta-Analysis of Toxicity Predictors and the Missing Evidence in BFM Protocols. Pediatric Hematology Oncology Journal. 2026:101191. doi:10.1016/j.phoj.2026.101191
BibTeX
@article{Alhassan2026,
author = {Alhassan, Moses O. and Dushimova, Z. and Milicevic, Milena Santric},
title = {Can Genetic Clues Make Chemotherapy Safer for Children with Leukemia? A Systematic Review and Meta-Analysis of Toxicity Predictors and the Missing Evidence in BFM Protocols},
journal = {Pediatric Hematology Oncology Journal},
year = {2026},
pages = {101191},
doi = {10.1016/j.phoj.2026.101191}
}
EUVIMED